Review



t cell activation transacttm miltenyi biotec  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Miltenyi Biotec t cell activation transacttm miltenyi biotec
    T Cell Activation Transacttm Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1677 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/CD8+MicroBeads%2C+human/pm42519827-287-76-80
    Average 97 stars, based on 1677 article reviews
    t cell activation transacttm miltenyi biotec - by Bioz Stars, 2026-09
    97/100 stars

    Images

    Related Articles

    other:

    Article Title: Perfusion microbioreactor for CAR-Treg manufacturing
    Article Snippet: Human T-Activator CD3/CD28 Dynabeads (Thermo Fisher Scientific) were added at a 1:1 cell to bead ratio and cells were maintained in culture for up to 12 days.

    Article Title: Metformin drives HIF-1α–mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer
    Article Snippet: T Cell TransActTM (130–111–160, Miltenyi Biotec) was used for restimulation at a titer of 1:500 following the manufacturer’s established guidelines.

    Article Title: Perfusion microbioreactor for CAR-Treg manufacturing
    Article Snippet: 462 STAR Methods 463 Experimental model and study participant details 464 Epstein-Barr Virus (EBV) transformed cell lines 465 Cryopreserved B-lymphoblastic cell lines (B-LCLs) were thawed and re-suspended at 466 0.2 x 106 cells/mL in supplemented RPMI-1640 with the addition of 1mM glutaMAX 467 (Gibco), 10% heat-inactivated foetal bovine serum (FBS), 100 IU/mL penicillin and 100 468 μg/mL streptomycin (ThermoFisher, UK).

    Isolation:

    Article Title: Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer
    Article Snippet: Pan-T cell negative selection was performed by magnetic cell sorting (Pan T Cell Isolation Kit, human, 130-096-535, Miltenyi) from frozen PBMCs of autologous samples according to the manufacturer’s instructions. .. Isolated T cells were activated for 24 h using T Cell TransActTM, human (130-128-758, Miltenyi) with 1:500 IL-2 (1 × 10 5 IU/mL, 200-02-100UG, ThermoFisher) according to manufacturer’s instructions. .. Activated T cells were collected and stained with CellTracker Green (C2925, ThermoFisher) in RPMI, 1:1000 for 30 min at 37 °C.

    Article Title: Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy
    Article Snippet: Human BM-MNCs were isolated by gradient centrifugation using Ficoll–Paque Premium (Cytiva, Sweden) and preserved at −80°C until use. .. Human peripheral blood mononuclear cells were isolated by gradient centrifugation using Ficoll–Paque Premium (Cytiva, Sweden) and activated using T-Cell TransActTM (Miltenyi Biotec, Bergisch Gladbach, Germany) in 24-well plates. .. Isolated T cells were activated in TexMACS medium (Miltenyi Biotec) and 5% FBS, supplemented with 50 U/ml human interleukin (IL)-2 (Miltenyi Biotec) for 48-72 h before use.

    Gradient Centrifugation:

    Article Title: Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy
    Article Snippet: Human BM-MNCs were isolated by gradient centrifugation using Ficoll–Paque Premium (Cytiva, Sweden) and preserved at −80°C until use. .. Human peripheral blood mononuclear cells were isolated by gradient centrifugation using Ficoll–Paque Premium (Cytiva, Sweden) and activated using T-Cell TransActTM (Miltenyi Biotec, Bergisch Gladbach, Germany) in 24-well plates. .. Isolated T cells were activated in TexMACS medium (Miltenyi Biotec) and 5% FBS, supplemented with 50 U/ml human interleukin (IL)-2 (Miltenyi Biotec) for 48-72 h before use.



    Similar Products

    97
    Miltenyi Biotec t cell activation transacttm miltenyi biotec
    T Cell Activation Transacttm Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/CD8+MicroBeads%2C+human/pm42519827-287-76-80
    Average 97 stars, based on 1 article reviews
    t cell activation transacttm miltenyi biotec - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human t cell 680 transacttm
    Human T Cell 680 Transacttm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/T+Cell+TransAct+%2C+human/pm42478044-264-42-47
    Average 97 stars, based on 1 article reviews
    human t cell 680 transacttm - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human t cell transacttm
    Human T Cell Transacttm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/T+Cell+TransAct+%2C+human/pm42410265-295-29-33
    Average 97 stars, based on 1 article reviews
    human t cell transacttm - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec t cell transacttm
    a Representative images of TNBC patient tissue stained with anti-panCK (DAB) for tumor cells and anti-CD8 (VIP) for CD8+ cytotoxic T cells. Scale bar = 100 µm. Tumor and stroma annotations and CD8 <t>T</t> <t>cell</t> detections performed using QuPath as illustrated. Intensity features for annotations calculated using QuPath. N = 18 tissues. b Pearson’s r value for correlative analysis of CD8% in the stroma compared to CD8% in the tumor. Red = inflamed, green = excluded, blue = desert. N = 17 tissues. c Pie chart showing distribution of phenotypes for 17 tissues. ECM N-linked glycans assigned to four main groups (Complex, purple; Hybrid, dark red; High-mannose, red; Paucimannose, orange). Stacked barchart displaying the proportion of each family in the N-glycome for d , mean inflamed and excluded samples and individual e , inflamed or f , excluded samples. g – i ECM N-linked complex glycans assigned to four main groups (Non-Sialyl, blue; Mono-Sialyl, orange; Di-Sialyl, red; Tri-Sialyl, dark red; Tetra-Sialyl,, purple). Stacked barchart displaying the proportion of each family in the N-glycome for g , mean inflamed and excluded samples and individual h , inflamed or i , excluded samples. d – i Mean with SD. Two-way Repeated Measures ANOVA with Šídák’s multiple comparisons test, N = 4 excluded tissues, N = 3 inflamed tissues.
    T Cell Transacttm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/T+Cell+TransAct+%2C+human/pmc13273098-430-9-14
    Average 97 stars, based on 1 article reviews
    t cell transacttm - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec t cell transact , human
    a Representative images of TNBC patient tissue stained with anti-panCK (DAB) for tumor cells and anti-CD8 (VIP) for CD8+ cytotoxic T cells. Scale bar = 100 µm. Tumor and stroma annotations and CD8 <t>T</t> <t>cell</t> detections performed using QuPath as illustrated. Intensity features for annotations calculated using QuPath. N = 18 tissues. b Pearson’s r value for correlative analysis of CD8% in the stroma compared to CD8% in the tumor. Red = inflamed, green = excluded, blue = desert. N = 17 tissues. c Pie chart showing distribution of phenotypes for 17 tissues. ECM N-linked glycans assigned to four main groups (Complex, purple; Hybrid, dark red; High-mannose, red; Paucimannose, orange). Stacked barchart displaying the proportion of each family in the N-glycome for d , mean inflamed and excluded samples and individual e , inflamed or f , excluded samples. g – i ECM N-linked complex glycans assigned to four main groups (Non-Sialyl, blue; Mono-Sialyl, orange; Di-Sialyl, red; Tri-Sialyl, dark red; Tetra-Sialyl,, purple). Stacked barchart displaying the proportion of each family in the N-glycome for g , mean inflamed and excluded samples and individual h , inflamed or i , excluded samples. d – i Mean with SD. Two-way Repeated Measures ANOVA with Šídák’s multiple comparisons test, N = 4 excluded tissues, N = 3 inflamed tissues.
    T Cell Transact , Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/T+Cell+TransAct+%2C+human/custom%40130-128-758%4042056521
    Average 97 stars, based on 1 article reviews
    t cell transact , human - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec t cell transacttm kit
    (A) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated αβ <t>T</t> <t>cell</t> recovery 24 h after thawing (n = 4 healthy donors). (B) 4-OI (50 μM) and Rosi (50 μM)-pretreated activated αβ T cell ADCC assay using anti-CD3/CD20 antibody. T cells were cultured with Raji cells at the 5:1, 10:1 and 20:1 effector:target ratio for 24 h (n = 3 healthy donors). (C) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (10 mM), 4-OI (200 μM) and/or Rosi (50 μM)-treated activated macrophages recovery 24 h after thawing. (D) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated γδ T cell recovery 24 h after thawing (n = 4 healthy donors). (E) 2-DG (8 mM), or 4-OI (50 μM) + Rosi (50 μM)-pretreated activated γδ cytotoxicity assay with K562 cells (n = 3 healthy donors). (F) Normalized survival of mice transplanted γδ T cell (n = 3 mice/group). (G) IFN-γ levels of blood in treated mice (n = 3 mice/group). (H) Schematic diagram for vivo experiment. (I) Tumor growth in mice. (J) Luminescent images of treated mice (n = 5 mice/group). Data are the mean ± SEM (A to G, and I). Statistical analysis was performed using an unpaired two-tailed Student’s t test. Ns, P >0.05, *P <0.05, **P <0.01, ***P <0.001. Cryo: cryopreserved cells; Non-Cryo: non-cryopreserved cells.
    T Cell Transacttm Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/T+Cell+TransAct+%2C+human/bio_rxiv__64898__2026__03__26__714376-203-17-21
    Average 97 stars, based on 1 article reviews
    t cell transacttm kit - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec macs gmp t cell transacttm large scale cr gmp
    (A) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated αβ <t>T</t> <t>cell</t> recovery 24 h after thawing (n = 4 healthy donors). (B) 4-OI (50 μM) and Rosi (50 μM)-pretreated activated αβ T cell ADCC assay using anti-CD3/CD20 antibody. T cells were cultured with Raji cells at the 5:1, 10:1 and 20:1 effector:target ratio for 24 h (n = 3 healthy donors). (C) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (10 mM), 4-OI (200 μM) and/or Rosi (50 μM)-treated activated macrophages recovery 24 h after thawing. (D) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated γδ T cell recovery 24 h after thawing (n = 4 healthy donors). (E) 2-DG (8 mM), or 4-OI (50 μM) + Rosi (50 μM)-pretreated activated γδ cytotoxicity assay with K562 cells (n = 3 healthy donors). (F) Normalized survival of mice transplanted γδ T cell (n = 3 mice/group). (G) IFN-γ levels of blood in treated mice (n = 3 mice/group). (H) Schematic diagram for vivo experiment. (I) Tumor growth in mice. (J) Luminescent images of treated mice (n = 5 mice/group). Data are the mean ± SEM (A to G, and I). Statistical analysis was performed using an unpaired two-tailed Student’s t test. Ns, P >0.05, *P <0.05, **P <0.01, ***P <0.001. Cryo: cryopreserved cells; Non-Cryo: non-cryopreserved cells.
    Macs Gmp T Cell Transacttm Large Scale Cr Gmp, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/t+cell+transacttm/MACS+GMP+T+Cell+TransAct+Large+Scale+CR%2FGMP/10__3390_slash_pharmaceutics18040414-70-17-25
    Average 95 stars, based on 1 article reviews
    macs gmp t cell transacttm large scale cr gmp - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    Image Search Results


    a Representative images of TNBC patient tissue stained with anti-panCK (DAB) for tumor cells and anti-CD8 (VIP) for CD8+ cytotoxic T cells. Scale bar = 100 µm. Tumor and stroma annotations and CD8 T cell detections performed using QuPath as illustrated. Intensity features for annotations calculated using QuPath. N = 18 tissues. b Pearson’s r value for correlative analysis of CD8% in the stroma compared to CD8% in the tumor. Red = inflamed, green = excluded, blue = desert. N = 17 tissues. c Pie chart showing distribution of phenotypes for 17 tissues. ECM N-linked glycans assigned to four main groups (Complex, purple; Hybrid, dark red; High-mannose, red; Paucimannose, orange). Stacked barchart displaying the proportion of each family in the N-glycome for d , mean inflamed and excluded samples and individual e , inflamed or f , excluded samples. g – i ECM N-linked complex glycans assigned to four main groups (Non-Sialyl, blue; Mono-Sialyl, orange; Di-Sialyl, red; Tri-Sialyl, dark red; Tetra-Sialyl,, purple). Stacked barchart displaying the proportion of each family in the N-glycome for g , mean inflamed and excluded samples and individual h , inflamed or i , excluded samples. d – i Mean with SD. Two-way Repeated Measures ANOVA with Šídák’s multiple comparisons test, N = 4 excluded tissues, N = 3 inflamed tissues.

    Journal: Nature Communications

    Article Title: Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer

    doi: 10.1038/s41467-026-73467-5

    Figure Lengend Snippet: a Representative images of TNBC patient tissue stained with anti-panCK (DAB) for tumor cells and anti-CD8 (VIP) for CD8+ cytotoxic T cells. Scale bar = 100 µm. Tumor and stroma annotations and CD8 T cell detections performed using QuPath as illustrated. Intensity features for annotations calculated using QuPath. N = 18 tissues. b Pearson’s r value for correlative analysis of CD8% in the stroma compared to CD8% in the tumor. Red = inflamed, green = excluded, blue = desert. N = 17 tissues. c Pie chart showing distribution of phenotypes for 17 tissues. ECM N-linked glycans assigned to four main groups (Complex, purple; Hybrid, dark red; High-mannose, red; Paucimannose, orange). Stacked barchart displaying the proportion of each family in the N-glycome for d , mean inflamed and excluded samples and individual e , inflamed or f , excluded samples. g – i ECM N-linked complex glycans assigned to four main groups (Non-Sialyl, blue; Mono-Sialyl, orange; Di-Sialyl, red; Tri-Sialyl, dark red; Tetra-Sialyl,, purple). Stacked barchart displaying the proportion of each family in the N-glycome for g , mean inflamed and excluded samples and individual h , inflamed or i , excluded samples. d – i Mean with SD. Two-way Repeated Measures ANOVA with Šídák’s multiple comparisons test, N = 4 excluded tissues, N = 3 inflamed tissues.

    Article Snippet: Isolated T cells were activated for 24 h using T Cell TransActTM, human (130-128-758, Miltenyi) with 1:500 IL-2 (1 × 10 5 IU/mL, 200-02-100UG, ThermoFisher) according to manufacturer’s instructions.

    Techniques: Staining

    a Schematic of a fluorescence-based live confocal imaging assay using decellularized tissue. Created in BioRender (Tarantola, L., 2026) https://BioRender.com/de0fus5 . b Representative images of adjacent and tumor decellularized tissue recellularized with mCherry HCC38 TNBC cells (red) and T cells (green) with ECM stained with anti-FN1-AF405 (blue). Scale bar = 100 µm. Total T cell number per field of view (FOV) ( c ) and T cell number near (<5 µm) or far (> 5 µm) from cancer cells ( d ) in tumor and adjacent tissues. N = 3 donors/group, 5–10 FOV/tissue. Error bars represent mean ± SD. Density distributions of T cell speed ( e ) and track length ( f ) near (<5 µm) cancer cells on tumor (red) and adjacent (orange) tissue. N = 3 tumor and N = 3 adjacent tissues, 2 technical replicates each. Density distributions of T cell speed ( g ) and track length ( h ) near (<5 µm) or far (>5 µm) from cancer cells in tumor tissue. N = 3 tumor tissues, 2 technical replicates each. c – h Dashed lines indicate medians. Data are presented in log scale. Kruskal–Wallis test with Dunn’s multiple comparisons test (two-sided, adjusted for multiple comparisons). i Representative images of tumor control tissue and tumor tissue treated with PNGase F or neuraminidase and recellularized with mCherry HCC38 TNBC cells (red) and T cells (green), with ECM stained with anti-FN1-AF405 (blue). Scale bar = 100 µm. Total T cell number per FOV ( j ), T cells near cancer cells (<5 µm) ( k ), and far from cancer cells (>5 µm) ( l ). N = 3 donors, 6–10 FOV/tissue. Error bars represent mean ± SD. Density distributions of T cell speed ( m ) and track length ( n ) near (<5 µm) cancer cells on tumor (red), PNGase F-treated (violet), or neuraminidase-treated (green) tissue. Dashed lines indicate medians. Data are presented in log scale. N = 3 tumor tissues, 2 technical replicates each. j – n Kruskal–Wallis test with Dunn’s multiple comparisons test (two-sided, adjusted for multiple comparisons).

    Journal: Nature Communications

    Article Title: Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer

    doi: 10.1038/s41467-026-73467-5

    Figure Lengend Snippet: a Schematic of a fluorescence-based live confocal imaging assay using decellularized tissue. Created in BioRender (Tarantola, L., 2026) https://BioRender.com/de0fus5 . b Representative images of adjacent and tumor decellularized tissue recellularized with mCherry HCC38 TNBC cells (red) and T cells (green) with ECM stained with anti-FN1-AF405 (blue). Scale bar = 100 µm. Total T cell number per field of view (FOV) ( c ) and T cell number near (<5 µm) or far (> 5 µm) from cancer cells ( d ) in tumor and adjacent tissues. N = 3 donors/group, 5–10 FOV/tissue. Error bars represent mean ± SD. Density distributions of T cell speed ( e ) and track length ( f ) near (<5 µm) cancer cells on tumor (red) and adjacent (orange) tissue. N = 3 tumor and N = 3 adjacent tissues, 2 technical replicates each. Density distributions of T cell speed ( g ) and track length ( h ) near (<5 µm) or far (>5 µm) from cancer cells in tumor tissue. N = 3 tumor tissues, 2 technical replicates each. c – h Dashed lines indicate medians. Data are presented in log scale. Kruskal–Wallis test with Dunn’s multiple comparisons test (two-sided, adjusted for multiple comparisons). i Representative images of tumor control tissue and tumor tissue treated with PNGase F or neuraminidase and recellularized with mCherry HCC38 TNBC cells (red) and T cells (green), with ECM stained with anti-FN1-AF405 (blue). Scale bar = 100 µm. Total T cell number per FOV ( j ), T cells near cancer cells (<5 µm) ( k ), and far from cancer cells (>5 µm) ( l ). N = 3 donors, 6–10 FOV/tissue. Error bars represent mean ± SD. Density distributions of T cell speed ( m ) and track length ( n ) near (<5 µm) cancer cells on tumor (red), PNGase F-treated (violet), or neuraminidase-treated (green) tissue. Dashed lines indicate medians. Data are presented in log scale. N = 3 tumor tissues, 2 technical replicates each. j – n Kruskal–Wallis test with Dunn’s multiple comparisons test (two-sided, adjusted for multiple comparisons).

    Article Snippet: Isolated T cells were activated for 24 h using T Cell TransActTM, human (130-128-758, Miltenyi) with 1:500 IL-2 (1 × 10 5 IU/mL, 200-02-100UG, ThermoFisher) according to manufacturer’s instructions.

    Techniques: Fluorescence, Imaging, Staining, Control

    a Schematic of macrophage decellularized tissue culture co-cultured with donor-matched T cells, with or without cancer cell (CC) media. Monocytes from three separate blood donors were cultured for 14 days on tumor ( N = 3) or adjacent (N = 3) decellularized tissues treated with neuraminidase (Neu) or sodium acetate vehicle control. Flow gating strategy provided in Supplementary Fig. . Created in BioRender. Tarantola, L. (2026) https://BioRender.com/ohvhmfy . Stacked bar of b activation markers (ICOS & CD137) or c exhaustion markers (PD1, LAG3, TIM3) shown as percentage positive cells expressing one marker, two markers or three markers from the T cell population. Error bars represent mean ± SD. 2way ANOVA test. N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones). d Barchart of flow cytometry expression patterns of PD1, LAG3 and TIGIT shown as percentage of positive cells from T cell population. Line at mean with standard deviation error bars Mixed-effects analysis with Tukey’s multiple comparisons adjustment test (two-sided). N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones). e Heatmap showing log10-transformed concentrations (pg/mL) of 8 cytokines (IFN-γ, TNF-α, IL-6, IL-10, IL-12p70, IL-17A, IL-18 and IL-23) measured in culture supernatants from macrophage (MAM) and T cell co-cultures grown on decellularized adjacent or tumor ECM scaffolds, in the absence or presence of cancer cell–conditioned medium (CC). ECM scaffolds were either untreated or treated with neuraminidase (Neu) prior to cell seeding. N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones). Overlaid numbers indicate paired t-test p-values for comparisons between untreated and Neu-treated ECM within the same tissue and CC condition. f Barchart of flow cytometry expression patterns of CD62L and CD162 shown as percentage of positive cells from T cell population. Line at mean with standard deviation error bars. Mixed-effects analysis with Tukey’s multiple comparisons adjustment test (two-sided). N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones).

    Journal: Nature Communications

    Article Title: Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer

    doi: 10.1038/s41467-026-73467-5

    Figure Lengend Snippet: a Schematic of macrophage decellularized tissue culture co-cultured with donor-matched T cells, with or without cancer cell (CC) media. Monocytes from three separate blood donors were cultured for 14 days on tumor ( N = 3) or adjacent (N = 3) decellularized tissues treated with neuraminidase (Neu) or sodium acetate vehicle control. Flow gating strategy provided in Supplementary Fig. . Created in BioRender. Tarantola, L. (2026) https://BioRender.com/ohvhmfy . Stacked bar of b activation markers (ICOS & CD137) or c exhaustion markers (PD1, LAG3, TIM3) shown as percentage positive cells expressing one marker, two markers or three markers from the T cell population. Error bars represent mean ± SD. 2way ANOVA test. N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones). d Barchart of flow cytometry expression patterns of PD1, LAG3 and TIGIT shown as percentage of positive cells from T cell population. Line at mean with standard deviation error bars Mixed-effects analysis with Tukey’s multiple comparisons adjustment test (two-sided). N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones). e Heatmap showing log10-transformed concentrations (pg/mL) of 8 cytokines (IFN-γ, TNF-α, IL-6, IL-10, IL-12p70, IL-17A, IL-18 and IL-23) measured in culture supernatants from macrophage (MAM) and T cell co-cultures grown on decellularized adjacent or tumor ECM scaffolds, in the absence or presence of cancer cell–conditioned medium (CC). ECM scaffolds were either untreated or treated with neuraminidase (Neu) prior to cell seeding. N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones). Overlaid numbers indicate paired t-test p-values for comparisons between untreated and Neu-treated ECM within the same tissue and CC condition. f Barchart of flow cytometry expression patterns of CD62L and CD162 shown as percentage of positive cells from T cell population. Line at mean with standard deviation error bars. Mixed-effects analysis with Tukey’s multiple comparisons adjustment test (two-sided). N = 3 ( N = 3 adjacent, N = 3 tumor, N = 3 blood cones).

    Article Snippet: Isolated T cells were activated for 24 h using T Cell TransActTM, human (130-128-758, Miltenyi) with 1:500 IL-2 (1 × 10 5 IU/mL, 200-02-100UG, ThermoFisher) according to manufacturer’s instructions.

    Techniques: Cell Culture, Control, Activation Assay, Expressing, Marker, Flow Cytometry, Standard Deviation, Transformation Assay

    (A) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated αβ T cell recovery 24 h after thawing (n = 4 healthy donors). (B) 4-OI (50 μM) and Rosi (50 μM)-pretreated activated αβ T cell ADCC assay using anti-CD3/CD20 antibody. T cells were cultured with Raji cells at the 5:1, 10:1 and 20:1 effector:target ratio for 24 h (n = 3 healthy donors). (C) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (10 mM), 4-OI (200 μM) and/or Rosi (50 μM)-treated activated macrophages recovery 24 h after thawing. (D) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated γδ T cell recovery 24 h after thawing (n = 4 healthy donors). (E) 2-DG (8 mM), or 4-OI (50 μM) + Rosi (50 μM)-pretreated activated γδ cytotoxicity assay with K562 cells (n = 3 healthy donors). (F) Normalized survival of mice transplanted γδ T cell (n = 3 mice/group). (G) IFN-γ levels of blood in treated mice (n = 3 mice/group). (H) Schematic diagram for vivo experiment. (I) Tumor growth in mice. (J) Luminescent images of treated mice (n = 5 mice/group). Data are the mean ± SEM (A to G, and I). Statistical analysis was performed using an unpaired two-tailed Student’s t test. Ns, P >0.05, *P <0.05, **P <0.01, ***P <0.001. Cryo: cryopreserved cells; Non-Cryo: non-cryopreserved cells.

    Journal: bioRxiv

    Article Title: A Conserved Metabolic–Oxidative Axis Underlies Immune Cell Cryo-vulnerability

    doi: 10.64898/2026.03.26.714376

    Figure Lengend Snippet: (A) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated αβ T cell recovery 24 h after thawing (n = 4 healthy donors). (B) 4-OI (50 μM) and Rosi (50 μM)-pretreated activated αβ T cell ADCC assay using anti-CD3/CD20 antibody. T cells were cultured with Raji cells at the 5:1, 10:1 and 20:1 effector:target ratio for 24 h (n = 3 healthy donors). (C) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (10 mM), 4-OI (200 μM) and/or Rosi (50 μM)-treated activated macrophages recovery 24 h after thawing. (D) LY294002 (25 μM), Rapamycin (2 μM), 2-DG (8 mM), 4-OI (50 μM) and/or Rosi (50 μM)-treated activated γδ T cell recovery 24 h after thawing (n = 4 healthy donors). (E) 2-DG (8 mM), or 4-OI (50 μM) + Rosi (50 μM)-pretreated activated γδ cytotoxicity assay with K562 cells (n = 3 healthy donors). (F) Normalized survival of mice transplanted γδ T cell (n = 3 mice/group). (G) IFN-γ levels of blood in treated mice (n = 3 mice/group). (H) Schematic diagram for vivo experiment. (I) Tumor growth in mice. (J) Luminescent images of treated mice (n = 5 mice/group). Data are the mean ± SEM (A to G, and I). Statistical analysis was performed using an unpaired two-tailed Student’s t test. Ns, P >0.05, *P <0.05, **P <0.01, ***P <0.001. Cryo: cryopreserved cells; Non-Cryo: non-cryopreserved cells.

    Article Snippet: Human αβ T cells were isolated and activated from human peripheral blood mononuclear cells (PBMCs) using the T Cell TransActTM kit (Miltenyi Biotec, #130-111-160), in strict accordance with the manufacturer’s protocol.

    Techniques: Cell Recovery, ADCC Assay, Cell Culture, Cytotoxicity Assay, Two Tailed Test